Drug intelligence / Profile preview

gaillardin

Development stage: Preclinical
Modality: Small Molecules

Overview

Gaillardin is a sesquiterpene lactone phytochemical that functions as a structural and functional modulator of tumor necrosis factor-alpha (TNF-alpha). It interacts with TNF-alpha through hydrogen bonding and van der Waals contacts (specifically involving residues GLN47 and ASP45), which stabilizes the protein's beta-sheet architecture and enhances its resistance to unfolding. In preclinical models of colorectal cancer, gaillardin has been shown to significantly increase the apoptotic activity of TNF-alpha, effectively lowering the IC50 and potentially addressing TNF-alpha hyporesponsiveness in tumor cells.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on gaillardin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gaillardin.

Explore the full profile